Robert Schuster, MD
General Practice · Dadeville, ALNPI 1871525931
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 700 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 12.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,683, 3.0 times the $883 reported in 2019. Among general practice clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 700 payments — averaging $17.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$2K
- GSK$1K
- AbbVie$1K
- Alkermes, Inc.$1K
- Neurocrine Biosciences, Inc.$1K
- Vanda Pharmaceuticals Inc.$1K
- plus $4K from 28 others
What the payments were for
- Food & beverage$12,29899%
- Education$861%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 112 | $1,534 |
| GSK | 74 | $1,465 |
| AbbVie(2 entities) | 122 | $1,395 |
| Alkermes, Inc. | 77 | $1,393 |
| Neurocrine Biosciences, Inc. | 49 | $1,092 |
| Vanda Pharmaceuticals Inc. | 46 | $1,024 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 44 | $851 |
| AstraZeneca | 28 | $794 |
| Bayer | 24 | $477 |
| Teva Pharmaceuticals USA, Inc. | 29 | $474 |
| Johnson & Johnson | 20 | $433 |
| Amgen | 9 | $182 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $174 |
| Novo Nordisk | 5 | $131 |
| Pfizer | 7 | $119 |
| Lundbeck LLC | 5 | $112 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $90 |
| Axsome Therapeutics, Inc. | 5 | $82 |
| Astellas Pharma US Inc | 1 | $80 |
| Indivior Inc. | 5 | $78 |
| Mylan Specialty L.p. | 3 | $52 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $43 |
| Ardelyx, Inc. | 2 | $43 |
| Novartis | 2 | $37 |
| Lilly USA, LLC | 3 | $34 |
| Biohaven Pharmaceuticals, Inc. | 2 | $30 |
| Philips North America LLC | 2 | $26 |
| Shire North American Group Inc | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Edwards Lifesciences | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Dexcom, Inc. | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$213
- AREXVY$124
- FASENRA$111
- Fanapt$108
- INGREZZA$102
How this compares
$12,384 in reported general payments places this provider in the 95th percentile of 1,114 general practice providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 81 | $260,618 |
| AustedoDeutetrabenazine | 25 | $219,770 |
| Abilify MaintenaAripiprazole | 77 | $195,557 |
| EliquisApixaban | 472 | $175,257 |
| IngrezzaValbenazine Tosylate | 19 | $164,771 |
| RexultiBrexpiprazole | 95 | $155,842 |
| FarxigaDapagliflozin Propanediol | 207 | $153,836 |
| MounjaroTirzepatide | 144 | $151,764 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 124 | $150,274 |
| OzempicSemaglutide | 103 | $116,497 |
| Invega TrinzaPaliperidone Palmitate | 13 | $109,541 |
| JardianceEmpagliflozin | 146 | $103,184 |
| LinzessLinaclotide | 80 | $70,076 |
| LybalviOlanzapine/Samidorphan Malate | 38 | $62,035 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 49 | $59,295 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta, Xarelto | $433 | $414,154120 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,534 | $351,398172 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $794 | $225,316294 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $474 | $219,77025 claims |
| PfizerEliquis | $119 | $175,257472 claims |
| Novo NordiskOzempic, Rybelsus | $131 | $172,224137 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,092 | $164,77119 claims |
| Lilly USA, LLCMounjaro | $34 | $151,764144 claims |
| GSKTrelegy Ellipta | $1,465 | $150,274124 claims |
| AbbVieLinzess, Vraylar, Viberzi | $1,395 | $118,653109 claims |
| Alkermes, Inc.Lybalvi, Aristada | $1,393 | $118,39855 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $851 | $34,27318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,114 general practice providers in Alabama.
Other general practice in Dadeville
- John DurantDadeville$5K
- Frank TombrelloBirmingham$163K
- Bradley WillisMontgomery$151K
- Ashley McIntyreMontgomery$123K
- John BurgessBirmingham$117K
- Glenn HarnettHoover$113K
- Alan ColemanAthens$30K
- Darrell DoucetteHuntsville$20K
- Earl RogersMobile$19K
- Jennifer DoobrowCullman$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.